Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D WHEATLEY

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Minerva Pediatrica|April 14, 2018
Efficacy of anthropometric measures for identifying cardiovascular disease risk in adolescents: review and meta-analysisMichael Lichtenauer, Sean D Wheatley, Marrissa Martyn-St James, et al.
ESMO Open|June 18, 2025
Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trialA Llombart-Cussac, J M Pérez-García, M Bellet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2022
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancerN C Turner, C Swift, B Jenkins, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Minerva Pediatrica|April 14, 2018
Efficacy of anthropometric measures for identifying cardiovascular disease risk in adolescents: review and meta-analysisMichael Lichtenauer, Sean D Wheatley, Marrissa Martyn-St James, et al.
ESMO Open|June 18, 2025
Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trialA Llombart-Cussac, J M Pérez-García, M Bellet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2022
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancerN C Turner, C Swift, B Jenkins, et al.
Pageof 8